Panakeia's Innovative Molecular Profiling Tool

Panakeia, a leader in the integration of artificial intelligence and multi-omic biomarker profiling, has announced that it will unveil impressive results from a rigorous validation study of its innovative molecular profiling tool, PANProfiler Colon, at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium. This prestigious event will be held from January 23-25, 2025, in San Francisco, CA, and is expected to attract global attention from medical professionals and cancer researchers alike.

Key Features of PANProfiler Colon

The PANProfiler Colon tool is specifically designed to evaluate Microsatellite Instability (MSI) and Mismatch Repair Deficiency (dMMR)—two critical markers in colorectal cancer—using advanced AI algorithms. Remarkably, the findings reveal that the software achieved an astounding 92.69% positive and 94.05% negative agreement for MSI/dMMR detection based on a comprehensive analysis of 3,178 colorectal cancer samples in a real-world blinded validation study. These statistics highlight PANProfiler's potential to revolutionize diagnosis, reducing the time from weeks to mere minutes in obtaining vital cancer biomarker information.

Presentation Details

The poster presentation, titled "Multi-site blinded validation of a deep learning approach for clinical-grade MSI/dMMR detection in colorectal cancer from H&E-stained pathology images," will take place in Session C: Cancers of the Colon, Rectum, and Anus, on January 25, 2025, from 7:00 AM to 7:55 AM PT.

Importance of MSI and dMMR Testing

Testing for MSI and dMMR markers is not merely an administrative formality; it plays an essential role in identifying Lynch syndrome—often referred to as hereditary nonpolyposis colorectal cancer (HNPCC)—and aids oncologists in making informed treatment decisions. The ramifications of these findings extend beyond diagnosis; they underscore the need for quicker, more efficient pathology processes that can lead to accelerated treatment timelines for patients.

CEO's Optimistic Outlook

Founder and CEO of Panakeia, Pahini Pandya, expressed optimism regarding the outcomes of the validation study. "The compelling performance of PANProfiler Colon is a game changer for pathologists and clinicians. We believe this software has the potential not only to expedite the diagnosis of colorectal cancer but also to facilitate personalized treatment strategies, making a real difference in patient care across the globe."

Global Availability and Future Potential

Currently, PANProfiler Colon is registered for clinical use in the UK, with the overarching PANProfiler platform available for research purposes worldwide. The platform is capable of profiling over 30 cancer types, providing expansive opportunities for patient screening and enrollment in clinical trials.

Conclusion

As we stand at the forefront of a new era in oncology, innovations like PANProfiler Colon could indeed redefine cancer diagnosis, offering patients faster access to tailored treatments and ultimately improving outcomes in the fight against colon cancer.

For More Information

For more information about Panakeia's groundbreaking technology, visit their official website at [Panakeia](https://www.panakeia.ai/).